Last reviewed · How we verify

NCT07056842

This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole

Completed Phase 1 Last updated 31 March 2026
What this trial tests

Phase 1 trial testing Rifampin + VCT220 in Obesity &Amp; Overweight in 32 participants. Completed in 30 September 2025.

Timeline
20 July 2025
Primary endpoint
11 August 2025
30 September 2025

Quick facts

Lead sponsorVincentage Pharma Co., Ltd
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Enrollment32
Start date20 July 2025
Primary completion11 August 2025
Estimated completion30 September 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Vincentage Pharma Co., Ltd — full company profile →

Who can join

Adults 18 to 50, any sex, with Obesity &Amp; Overweight. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite VCT289. Cohort 1 will assess the impact of rifampin (600 mg once daily) on VCT220 (160 mg single dose). Cohort 2 will assess the impact of itraconazole (200 mg once daily) on VCT220 (40 mg single dose). A total of 32 healthy subjects will be enrolled, 16 in each cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Obesity &Amp; Overweight

Currently open trials in the same condition.

Other Vincentage Pharma Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07056842.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing